Cerevance announces positive Phase 3 Arise results
Cerevance said its Phase 3 Arise study of once-daily oral solengepras met its primary endpoint and showed motor and non-motor benefits in Parkinson’s disease.
Cerevance said its Phase 3 Arise study of once-daily oral solengepras met its primary endpoint and showed motor and non-motor benefits in Parkinson’s disease.